Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone : analyses from the Phase II HORIZON study - Larocca, Alessandra (Azienda Ospedaliero - Universitaria Città della Salute e della Scienza) ; Leleu, Xavier (CHU de Poitiers) ; Touzeau, Cyrille (Université d'Angers) ; Bladé Creixenti, Juan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Paner, Agne (Rush University Medical Center) ; Mateos, M. V (Instituto de Investigación Biomédica de Salamanca) ; Cavo, Michele (Bologna University School of Medicine) ; Maisel, Christopher (Baylor Scott & White Charles A) ; Alegre, Adrian (Hospital Universitario de la Princesa (Madrid)) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Raptis, Anastasios (niversity of Pittsburgh School of Medicine) ; Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ; Mazumder, Amitabha (The Oncology Institute of Hope and Innovation) ; Laubach, Jacob (Harvard Medical School) ; Nadeem, Omar (Harvard Medical School) ; Sandberg, Anna (Oncopeptides AB (Suècia)) ; Orre, Marie (Oncopeptides AB (Suècia)) ; Torrång, Anna (SDS Life Science (Suècia)) ; Bakker, Nicolaas A (Oncopeptides AB) ; Richardson, Paul G.. (Harvard Medical School) ; Universitat Autònoma de Barcelona